A Phase 2 interventional study of Abemaciclib and LY3023414 in Pancreatic Ductal Adenocarcinoma, sponsored by Eli Lilly and Company. Completed at 32 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-20.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 369 studies testing gemcitabine in Pancreatic Neoplasms — 29 open to participants now, 44 under way, 5 of them phase 3. Gemcitabine · Pancreatic Neoplasms.
Among the 369 studies testing gemcitabine in Pancreatic Neoplasms, this one is the 61st largest by enrollment of the 352 interventional ones that give a count, is one of 7 that started in 2017, is one of 195 in phase 2, and was the 286th registered.
3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.
Browse Pancreatic Neoplasms studies →29 of the 369 studies testing gemcitabine in Pancreatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Revolution Medicines, Inc. · Sites in United States
Ages 18+
Smartwise Sweden AB · Sites in Sweden
Ages 18+
Revolution Medicines, Inc. · Sites in United States, Australia, Austria and 18 more countries
Ages 18+
Shanghai Hengrui Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →
Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
369 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 125 · Phase 2 238 · Phase 3 36 · Phase 4 2
First in 1995; this study’s year is marked. 7 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is above the median of 47 across 2,932 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 37 across the 352 interventional studies. Of the 268 that completed or were terminated, 80 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 369 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
25 studies in Pancreatic Neoplasms by Eli Lilly and Company: 2 open now, 5 under way, none of them phase 3. Of 18 finished, 11 (61%) have results posted.
Among the 25 studies in Pancreatic Neoplasms by Eli Lilly and Company, this one is the 15th largest by enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2017, is one of 7 in phase 2, and was the 16th registered.
Eli Lilly and Company’s Pancreatic Neoplasms studies by the year they started, since 2002.
15 of the studies testing gemcitabine in Pancreatic Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06953999Phase 3AkesoA Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer | 2027-05-14 |
| NCT02340117SynerGene Therapeutics, Inc.Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer | 2026-12 |
| NCT03652428University of Maryland, BaltimorePhase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC) | 2026-12-31 |
| NCT04115163Anne NoonanBiologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer | 2026-12-31 |
| NCT04894643EBG MedAustron GmbHPreoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 369 studies testing gemcitabine in Pancreatic Neoplasms, from their registry updates:
Among Eli Lilly and Company’s 25 in Pancreatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of abemaciclib alone and in combination with other drugs versus standard of care in participants with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate organ function.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Abemaciclib given orally.
Drug: Abemaciclib
Abemaciclib given orally and LY3023414 given orally.
Drug: Abemaciclib · Drug: LY3023414
Gemcitabine given intravenously (IV) OR capecitabine given orally.
Drug: Gemcitabine · Drug: Capecitabine
Administered orally
Also known as: LY2835219
Administered orally
Administered IV
Also known as: LY188011
Administered orally
Stage 1: Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD)
Disease control rate (DCR) is the percentage of participants with a best overall response of CR, PR or SD as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Time frame: Baseline to Measured Progressive Disease or Start of New Anticancer Therapy (Up to 6 Months)
Stage 2: Progression Free Survival (PFS)
PFS was defined as the time from the date of randomization until first observation of objective progressive disease as defined by RECIST v1.1 or death from any cause, whichever comes first. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a patient does not have a complete baseline disease assessment, then the PFS time will be censored at the randomization date, regardless of whether or not objectively determined disease progression or death has been observed for the patient; otherwise, if a patient is not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time will be censored at the last complete objective progression-free disease assessment date.
Time frame: Baseline to Measured Progressive Disease or Death Due to Any Cause (Up to 6 Months)
Stage 1: Objective Response Rate (ORR): Percentage of Participants With a Best Overall Response (BOR) of CR or PR
Objective response rate (ORR) is the percentage of participants with a BOR of CR or PR as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.
Time frame: Baseline to Measured Progressive Disease or Start of New Anti-Cancer Therapy (Up to 6 Months)
Stage 1: Pharmacokinetics (PK): Mean Steady State Exposure of Abemaciclib and Its Metabolites (LSN2839567 (M2), LSN3106726 (M20))
Mean steady state exposure was reported as measured by maximum observed plasma concentration (Cmax).
Time frame: Cycle(C)1 Day(D)14: 0 hour(h),0.5h,1h,2h,4h,6h,8h post dose
Stage 1: PK: Area Under the Curve (AUC) (AUC[Tau]) of LY3023414
Time frame: Cycle 1 Day 1 through Cycle 4 Day 1 (28 Day Cycles)
Stage 1: PK: Maximum Concentration (Cmax) at Steady State of LY3023414
Time frame: Cycle 1 Day 1 through Cycle 4 Day 1 (28 Day Cycles)
Stage 2: Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of CR, PR, and SD
Time frame: Baseline to Measured Progressive Disease or Start of New Anticancer Therapy (Up to 6 Months)
Stage 2: Clinical Benefit Rate (CBR): Percentage of Participants With Best Overall Response of CR, PR, or SD With Duration of SD for at Least 6 Months
Clinical benefit rate (CBR) is the percentage of participants with a BOR of CR or PR, or SD ≥6 months. CR is defined as the disappearance of all target and non-target lesions \& no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.
Time frame: Baseline to Disease Progression or Start of New Anticancer Therapy (Up to 6 Months)
Stage 2: Duration of Response (DoR)
Time frame: Date of CR or PR to Date of Disease Progression or Death Due to Any Cause (Up to 6 Months)
Stage 2: Overall Survival (OS)
OS duration is measured from the date of randomization to the date of death from any cause. for participants who is not known to have died as of the data-inclusion cutoff date, OS was censored at the last known alive date. No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.
Time frame: Baseline to Death from Any Cause (Up to 10 Months)
Stage 2: Change From Baseline in Carbohydrate Antigen 19.9 (CA 19-9) Level
No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.
Time frame: Baseline, 6 Months
Stage 2: Change From Baseline in Pain and Symptom Burden Assessment on the Modified Brief Pain Inventory-Short Form (mBPI-sf)
mBPI-sf is an 11-item instrument used as a multiple-item measure of cancer pain intensity. In addition to pain intensity (4 items), the mBPI-sf is designed for participants to record the presence of pain in general, pain relief, and pain interference with function (general activity, mood, ability to walk, ability to perform normal work, relations with others, sleep, and enjoyment of life). Responses for the mBPI-sf items are captured through the use of 11-point numeric rating scales anchored at 0 (no pain or does not interfere) and ranged through 10 (pain as bad as you can imagine or completely interferes). The mBPI-sf recall period is 24 hours, and typical completion time for this instrument is less than 5 minutes. No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.
Time frame: Baseline, 6 Months
Stage 2: Change From Baseline in Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)
The EORTC QLQ-C30 self-reported general cancer instrument consists of 30 items covered by 1 of 3 dimensions: 1. Global health status/quality of life (2 items) with scores ranging from 1 (Very Poor) to 7 (Excellent). 2. Functional scales (15 total items addressing either physical, role, emotional, cognitive, or social functioning), each item scores ranging from 1 (not at all) to 4 (very much) 3. Symptom scales (13 total items addressing either fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, or financial impact), each item scores ranging from 1 (not at all) to 4 (very much). Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function/QOL or higher levels of symptom burden. No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.
Time frame: Baseline, 6 Months
Stage 1: PK: Steady State Trough Pre Dose Concentration of LY3023414
Mean steady state exposure was reported by trough pre-dose plasma concentrations.
Time frame: C2D1: 0h, C3D1: 0h, C4D1: 0h
Stage 1: PK: Mean Single Dose Concentration of LY3023414 at 2h Post-dose
Mean single dose exposure was reported by plasma concentrations collected approximately 2 hours post-dose.
Time frame: C1D1: 2h Post dose
Study was planned for stage 1 \& stage 2. No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1. Completed participants are those who has CR, PR, SD, or PD and is off treatment.
| Milestone | 150mg Abemaciclib + 150mg Galunisertib (Safety Lead-in) | 200mg Abemaciclib | 150mg Abemaciclib + 150mg LY3023414 | Gemcitabine or Capecitabine |
|---|---|---|---|---|
| Started | 7 | 33 | 33 | 33 |
| Received at least one dose of study drug | 7 | 32 | 33 | 26 |
| Completed | 7 | 22 | 20 | 19 |
| Not completed | 0 | 11 | 13 | 14 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Withdrew: Death | 0 | 9 | 9 | 4 |
| Withdrew: Withdrawal by subject | 0 | 0 | 3 | 1 |
| Withdrew: Study closed by sponsor | 0 | 0 | 1 | 1 |
| Withdrew: Randomized, never treated | 0 | 1 | 0 | 7 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
Disease control rate (DCR) is the percentage of participants with a best overall response of CR, PR or SD as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
| percentage of Participants | 200mg Abemaciclib | 150mg Abemaciclib + 150mg LY3023414 | Gemcitabine or Capecitabine |
|---|---|---|---|
| Stage 1: Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) | 15.2 (2.9 to 27.4) | 12.1 (1.0 to 23.3) | 36.4 (20 to 52.8) |
PFS was defined as the time from the date of randomization until first observation of objective progressive disease as defined by RECIST v1.1 or death from any cause, whichever comes first. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a patient does not have a complete baseline disease assessment, then the PFS time will be censored at the randomization date, regardless of whether or not objectively determined disease progression or death has been observed for the patient; otherwise, if a patient is not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time will be censored at the last complete objective progression-free disease assessment date.
| Months | 200mg Abemaciclib | 150mg Abemaciclib + 150mg LY3023414 | Gemcitabine or Capecitabine |
|---|---|---|---|
| Stage 2: Progression Free Survival (PFS) | 1.68 (1.35 to 1.84) | 1.81 (1.28 to 1.91) | 3.25 (1.05 to 5.65) |
Objective response rate (ORR) is the percentage of participants with a BOR of CR or PR as defined by RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.
| percentage of Participants | 200mg Abemaciclib | 150mg Abemaciclib + 150mg LY3023414 | Gemcitabine or Capecitabine |
|---|---|---|---|
| Stage 1: Objective Response Rate (ORR): Percentage of Participants With a Best Overall Response (BOR) of CR or PR | 3 (0 to 8.9) | 0 (NA to NA) | 3 (0 to 8.9) |
Mean steady state exposure was reported as measured by maximum observed plasma concentration (Cmax).
| Nanogram per Millilitre (ng/mL) | 150mg Abemaciclib + 150mg Galunisertib |
|---|---|
| Abemaciclib | 356 ± 137 |
| LSN2839567 (M2) | 85.1 ± 66 |
| LSN3106726 (M20) | 153 ± 58 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Clinical benefit rate (CBR) is the percentage of participants with a BOR of CR or PR, or SD ≥6 months. CR is defined as the disappearance of all target and non-target lesions \& no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.
| percentage of participants | 200mg Abemaciclib | 150mg Abemaciclib + 150mg LY3023414 | Gemcitabine or Capecitabine |
|---|---|---|---|
| Stage 2: Clinical Benefit Rate (CBR): Percentage of Participants With Best Overall Response of CR, PR, or SD With Duration of SD for at Least 6 Months | 3 (0 to 8.9) | 0 (0 to 0) | 3 (0 to 8.9) |
No measurements were reported for this outcome.
OS duration is measured from the date of randomization to the date of death from any cause. for participants who is not known to have died as of the data-inclusion cutoff date, OS was censored at the last known alive date. No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.
| Months | 200mg Abemaciclib | 150mg Abemaciclib + 150mg LY3023414 | Gemcitabine or Capecitabine |
|---|---|---|---|
| Stage 2: Overall Survival (OS) | 2.71 (1.97 to 5.36) | 3.29 (1.97 to 5.03) | NA (2.53 to NA) |
No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.
| U/mL | 200mg Abemaciclib | 150mg Abemaciclib + 150mg LY3023414 | Gemcitabine or Capecitabine |
|---|---|---|---|
| Stage 2: Change From Baseline in Carbohydrate Antigen 19.9 (CA 19-9) Level | 4281.53 ± 8177.89 | 3225.29 ± 5730.25 | -501.17 ± 7198.70 |
mBPI-sf is an 11-item instrument used as a multiple-item measure of cancer pain intensity. In addition to pain intensity (4 items), the mBPI-sf is designed for participants to record the presence of pain in general, pain relief, and pain interference with function (general activity, mood, ability to walk, ability to perform normal work, relations with others, sleep, and enjoyment of life). Responses for the mBPI-sf items are captured through the use of 11-point numeric rating scales anchored at 0 (no pain or does not interfere) and ranged through 10 (pain as bad as you can imagine or completely interferes). The mBPI-sf recall period is 24 hours, and typical completion time for this instrument is less than 5 minutes. No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.
| score on a scale | 200mg Abemaciclib | 150mg Abemaciclib + 150mg LY3023414 | Gemcitabine or Capecitabine |
|---|---|---|---|
| Pain at its Worst in Last 24 hours | 0.63 ± 0.47 | -0.33 ± 0.55 | -0.02 ± 0.57 |
| Pain at its Least in Last 24 hours | 0.86 ± 0.42 | 0.18 ± 0.49 | 0.39 ± 0.51 |
| Pain on the Average | 0.62 ± 0.45 | -0.03 ± 0.51 | -0.07 ± 0.53 |
| Pain Right Now | 0.38 ± 0.34 | 0.34 ± 0.59 | -0.38 ± 0.61 |
| Pain Interfered General Activity | 0.64 ± 0.47 | 0.07 ± 0.55 | 0.22 ± 0.57 |
| Pain Interfered with Mood | 0.54 ± 0.41 | 0.28 ± 0.48 | 0.60 ± 0.50 |
| Pain Interfered Walking Ability | 0.05 ± 0.55 | 0.83 ± 0.64 | 0.19 ± 0.67 |
| Pain Interfered with Normal Work | 1.07 ± 0.51 | 0.66 ± 0.59 | 0.19 ± 0.61 |
| Pain Interfered with Relations | 0.39 ± 0.52 | 0.67 ± 0.61 | 0.26 ± 0.63 |
| Pain Interfered with Sleep | 0.19 ± 0.53 | 0.34 ± 0.61 | -0.56 ± 0.65 |
| Pain Interfered Enjoyment of Life | 0.69 ± 0.62 | 0.39 ± 0.72 | -0.13 ± 0.75 |
| BPI Mean Pain Interference Score | 0.55 ± 0.44 | 0.50 ± 0.51 | 0.05 ± 0.54 |
The EORTC QLQ-C30 self-reported general cancer instrument consists of 30 items covered by 1 of 3 dimensions: 1. Global health status/quality of life (2 items) with scores ranging from 1 (Very Poor) to 7 (Excellent). 2. Functional scales (15 total items addressing either physical, role, emotional, cognitive, or social functioning), each item scores ranging from 1 (not at all) to 4 (very much) 3. Symptom scales (13 total items addressing either fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, or financial impact), each item scores ranging from 1 (not at all) to 4 (very much). Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function/QOL or higher levels of symptom burden. No participants were enrolled to stage 2; however, results for stage 2 outcomes are reported from the data collected for participants enrolled to stage 1.
| units on a scale | 200mg Abemaciclib | 150mg Abemaciclib + 150mg LY3023414 | Gemcitabine or Capecitabine |
|---|---|---|---|
| Global Health Status | -6.21 ± 3.87 | -4.82 ± 4.50 | -2.40 ± 4.64 |
| Functional Scales: Physical Functioning | -14.44 ± 4.40 | -11.65 ± 5.12 | -5.42 ± 5.12 |
| Functional Scales: Role Functioning | -17.09 ± 6.17 | -18.05 ± 7.32 | -17.10 ± 7.36 |
| Functional Scales: Emotional Functioning | -4.89 ± 4.49 | -0.63 ± 5.22 | 2.06 ± 5.41 |
| Functional Scales: Cognitive Functioning | -10.43 ± 4.10 | -8.39 ± 4.77 | -5.18 ± 4.95 |
| Functional Scale: Social Functioning | -21.12 ± 4.90 | -17.09 ± 5.72 | -2.00 ± 5.95 |
| Symptom Scales: Fatigue | 14.13 ± 4.92 | 14.90 ± 5.73 | 5.64 ± 5.71 |
| Symptom Scales: Nausea and Vomiting | 7.98 ± 5.57 | 9.42 ± 6.47 | 11.88 ± 6.50 |
| Symptom Scales: Pain | 9.79 ± 5.63 | 2.68 ± 6.61 | 5.43 ± 6.62 |
| Symptom Scale: Dysopnea | 0.35 ± 5.48 | 11.19 ± 6.38 | -4.51 ± 6.36 |
| Symptom Scale: Insomnia | -5.19 ± 5.17 | 1.83 ± 6.01 | -6.71 ± 6.05 |
| Symptom Scale: Appetite Loss | 12.54 ± 5.79 | 15.32 ± 6.77 | 9.51 ± 7.30 |
| Symptom Scale: Constipation | 2.96 ± 5.95 | -6.51 ± 6.96 | 12.93 ± 7.15 |
| Symptom Scale: Diarrhoea | 15.71 ± 6.76 | 26.28 ± 7.83 | 20.51 ± 7.98 |
| Symptom Scale: Financial difficulties | 3.96 ± 4.82 | 2.45 ± 5.68 | -3.30 ± 5.87 |
Mean steady state exposure was reported by trough pre-dose plasma concentrations.
| ng/mL | 150mg Abemaciclib + 150mg LY3023414 |
|---|---|
| Stage 1: PK: Steady State Trough Pre Dose Concentration of LY3023414 | 27.3 ± 450 |
Mean single dose exposure was reported by plasma concentrations collected approximately 2 hours post-dose.
| ng/mL | 150mg Abemaciclib + 150mg LY3023414 |
|---|---|
| Stage 1: PK: Mean Single Dose Concentration of LY3023414 at 2h Post-dose | 518 ± 67 |
Collected over Up to 30 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 150mg Abemaciclib + 150mg Galunisertib (Safety Lead - In) | 5/7 (71.4%) | 4/7 (57.1%) | 7/7 (100%) |
| 200mg Abemaciclib | 22/32 (68.8%) | 17/32 (53.1%) | 30/32 (93.8%) |
| 150mg Abemaciclib + 150mg LY3023414 | 21/33 (63.6%) | 18/33 (54.5%) | 33/33 (100%) |
| Gemcitabine or Capecitabine | 12/26 (46.2%) | 15/26 (57.7%) | 25/26 (96.2%) |
| Event | 150mg Abemaciclib + 150mg Galunisertib (Safety Lead - In) | 200mg Abemaciclib | 150mg Abemaciclib + 150mg LY3023414 | Gemcitabine or Capecitabine |
|---|---|---|---|---|
| VomitingGastrointestinal disorders | 0/7 | 1/32 | 2/33 | 4/26 |
| AnaemiaBlood and lymphatic system disorders | 1/7 | 0/32 | 1/33 | 0/26 |
| Gastric ulcer haemorrhageGastrointestinal disorders | 1/7 | 0/32 | 0/33 | 0/26 |
| AstheniaGeneral disorders | 1/7 | 0/32 | 0/33 | 0/26 |
| FatigueGeneral disorders | 1/7 | 1/32 | 1/33 | 0/26 |
| Systemic inflammatory response syndromeGeneral disorders | 1/7 | 0/32 | 0/33 | 0/26 |
| SepsisInfections and infestations | 1/7 | 1/32 | 1/33 | 0/26 |
| UrosepsisInfections and infestations | 1/7 | 0/32 | 0/33 | 0/26 |
| Platelet count decreasedInvestigations | 1/7 | 0/32 | 1/33 | 0/26 |
| White blood cell count decreasedInvestigations | 1/7 | 0/32 | 0/33 | 0/26 |
| Event | 150mg Abemaciclib + 150mg Galunisertib (Safety Lead - In) | 200mg Abemaciclib | 150mg Abemaciclib + 150mg LY3023414 | Gemcitabine or Capecitabine |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 5/7 | 9/32 | 15/33 | 9/26 |
| DiarrhoeaGastrointestinal disorders | 4/7 | 12/32 | 17/33 | 8/26 |
| FatigueGeneral disorders | 4/7 | 16/32 | 17/33 | 11/26 |
| HyponatraemiaMetabolism and nutrition disorders | 4/7 | 1/32 | 3/33 | 1/26 |
| VomitingGastrointestinal disorders | 2/7 | 10/32 | 15/33 | 6/26 |
| AnaemiaBlood and lymphatic system disorders | 3/7 | 10/32 | 6/33 | 11/26 |
| Decreased appetiteMetabolism and nutrition disorders | 3/7 | 9/32 | 8/33 | 8/26 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 0/7 | 0/32 | 2/33 | 10/26 |
| StomatitisGastrointestinal disorders | 0/7 | 0/32 | 12/33 | 6/26 |
| Platelet count decreasedInvestigations | 0/7 | 10/32 | 5/33 | 4/26 |
| Age, Continuous(years) | 150mg Abemaciclib + 150mg Galunisertib (Safety Lead-in) | 200mg Abemaciclib | 150mg Abemaciclib + 150mg LY3023414 | Gemcitabine or Capecitabine | Total |
|---|---|---|---|---|---|
| Mean | 65.29 ± 6.99 | 61.09 ± 7.83 | 62.52 ± 8.97 | 66.85 ± 7.61 | 63.40 ± 8.34 |
| Sex: Female, Male(Participants) | 150mg Abemaciclib + 150mg Galunisertib (Safety Lead-in) | 200mg Abemaciclib | 150mg Abemaciclib + 150mg LY3023414 | Gemcitabine or Capecitabine | Total |
|---|---|---|---|---|---|
| Female | 4 | 18 | 16 | 19 | 57 |
| Male | 3 | 15 | 17 | 14 | 49 |
| Ethnicity (NIH/OMB)(Participants) | 150mg Abemaciclib + 150mg Galunisertib (Safety Lead-in) | 200mg Abemaciclib | 150mg Abemaciclib + 150mg LY3023414 | Gemcitabine or Capecitabine | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 4 | 3 | 9 |
| Not Hispanic or Latino | 7 | 30 | 28 | 24 | 89 |
| Unknown or Not Reported | 0 | 1 | 1 | 6 | 8 |
| Race (NIH/OMB)(Participants) | 150mg Abemaciclib + 150mg Galunisertib (Safety Lead-in) | 200mg Abemaciclib | 150mg Abemaciclib + 150mg LY3023414 | Gemcitabine or Capecitabine | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 7 | 5 | 4 | 16 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 3 | 4 |
| White | 7 | 26 | 26 | 25 | 84 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 | 2 |
| Region of Enrollment(Participants) | 150mg Abemaciclib + 150mg Galunisertib (Safety Lead-in) | 200mg Abemaciclib | 150mg Abemaciclib + 150mg LY3023414 | Gemcitabine or Capecitabine | Total |
|---|---|---|---|---|---|
| Belgium | 0 | 8 | 6 | 5 | 19 |
| United States | 7 | 8 | 10 | 8 | 33 |
| Taiwan | 0 | 7 | 4 | 3 | 14 |
| United Kingdom | 0 | 1 | 0 | 0 | 1 |
| Israel | 0 | 2 | 4 | 5 | 11 |
| Australia | 0 | 1 | 1 | 3 | 5 |
| France | 0 | 1 | 1 | 6 | 8 |
| Spain | 0 | 5 | 7 | 3 | 15 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement. More information provided by Eli Lilly and Company
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jan 2017 to primary completion in Apr 2018, 15 months.
Results were first posted in Jun 2019, 1 year 2 months after primary completion.
Of 69 industry-sponsored phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's 15 months is below that.
Counting every sponsor, half of 394 studies reached it within 57 months; a quarter within 35 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Abemaciclib · Gemcitabine · Capecitabine